Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

ction to PRADAXA (e.g., anaphylactic reaction or anaphylactic shock)
  • A mechanical prosthetic heart valve 
  • WARNINGS & PRECAUTIONS 
    Risk of Bleeding

    PRADAXA increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding.

    Risk factors for bleeding include concomitant use of medications that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). PRADAXA's anticoagulant activity and half-life are increased in patients with renal impairment. 

    A specific reversal agent for dabigatran is not available. Hemodialysis can remove dabigatran; however clinical experience for hemodialysis as a treatment for bleeding is limited. Activated prothrombin complex concentrates, recombinant Factor VIIa, or concentrates of factors II, IX or X may be considered but their use has not been evaluated. Protamine sulfate and vitamin K are not expected to affect dabigatran anticoagulant activity. Consider administration of platelet concentrates where thrombocytopenia is present or long-acting antiplatelet drugs have been used. 

    Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
    The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than 3 months prior to enrollment) was evaluated in the phase 2 RE-ALIGN trial. RE-ALIGN was terminated early because of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) for PRADAXA vs warfarin. Therefore, the use
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
    2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
    3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
    4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
    5. Shingles Vaccine is Safe, According to New Study
    6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
    7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
    8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
    9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
    11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
    (Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
    (Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
    Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
    ... 8 www.leebio.com , Lee Biosolutions, Inc,continues ... enzyme for,clinical diagnostic, pharmaceutical manufacturers and clinical researchers,worldwide ... Current research on this important ... inflammation to multiple sclerosis, diabetes,stroke and gastric cancer ...
    ... Dec. 8 Cell Therapeutics, Inc. (CTI),(Nasdaq ... follow-up data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line ... of Hematology (ASH) 50th Annual Meeting by,Morschhauser, ... progression-free,survival (PFS) following Zevalin consolidation therapy for ...
    Cached Medicine Technology:Myeloperoxidase Research Expands 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5
    (Date:4/24/2014)... April 24, 2014 ,Take me out to the ... and kale chips. The more likely culprits include French ... , Unfortunately for children who play youth baseball, eating ... to weight problems, according to researchers at Wake Forest ... online edition of Childhood Obesity , found that ...
    (Date:4/24/2014)... aspects, the corresponding terminology, and the relevance of ... in publications on randomized controlled trials (RCTs). This ... German Institute for Quality and Efficiency in Health ... final report. , Together with external experts, IQWiG ... glioblastoma, lung cancer, malignant melanoma, and pancreatic cancer. ...
    (Date:4/24/2014)... NH, 4/24/14) Dartmouth has been awarded one of ... serve as a Lead Academic Participating Site in its ... Award recipients are a select groups of investigators charged ... fewer cooperative groups., The NCTN grant system reflects recommendations ... It streamlines operations to achieve four goals:, ...
    (Date:4/23/2014)... (MGH) investigators may lead to greater availability and acceptability ... use of fecal material from healthy donors to ... ( C. difficile ) bacteria. In their ... Infectious Diseases , the researchers report that use of ... was as successful in curing recurrent C. difficile ...
    (Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
    Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2
    ... that virtually eliminated bloodstream infections in hospital intensive-care units ... 10 percent, a new study suggests. Although prior research ... at hospitals using the checklist, the new study is ... "We knew that when we applied safety science ...
    ... the tight barrier that protects the brain from the bloodstream ... research team led by scientists from The University of Texas ... the Journal of Clinical Investigation . In experiments ... payloads to image tumors, treat tumors, or can potentially do ...
    ... Steven Reinberg HealthDay Reporter , TUESDAY, Feb. ... arthritis, many of them minority patients, aren,t getting needed ... designed to slow progression of the deformities and disability ... early, expert guidelines say. "Both patients and ...
    ... S.C. More than 200 experts will gather at Clemson ... of play, and they already agree on one thing: Children ... of Play is attracting health professionals, educators, parents and park ... Value of Play, which led to the creation of the ...
    ... Reporter , TUESDAY, Feb. 1 (HealthDay News) -- Teenagers ... meningitis, a potentially deadly infection of the tissue around ... cough vaccines in light of recent outbreaks, according to ... of Pediatrics issues updated vaccination guidelines annually. Its new ...
    ... for Therapeutic Radiology and Oncology (ESTRO), the European Head ... Medical Oncology (ESMO) in collaboration with other European partners, ... the 3rd International Conference on innovative approaches In Head ... multidisciplinarity and innovation, this meeting will specifically cover the ...
    Cached Medicine News:Health News:Safety checklist use yields 10 percent drop in hospital deaths 2Health News:Safety checklist use yields 10 percent drop in hospital deaths 3Health News:Targeted particle fools brain's guardian to reach tumors 2Health News:Targeted particle fools brain's guardian to reach tumors 3Health News:Targeted particle fools brain's guardian to reach tumors 4Health News:Too Few Get Needed Rheumatoid Arthritis Drugs: Study 2Health News:Too Few Get Needed Rheumatoid Arthritis Drugs: Study 3Health News:Clemson conference attracts experts concerned about children's 'play deficit' 2Health News:Pediatricians Issue New Vaccination Recommendations 2Health News:Pediatricians Issue New Vaccination Recommendations 3Health News:3rd international conference on innovative approaches in head and neck oncology 2
    ... The UrinQuick Urine Chemistry Analyzer is ... analysis of urine test strips. The UrinQuick ... for QuickVue UrinChek 10+ SG and QuickVue ... analyzes the urine test strips by reflectance ...
    ... a qualitative assay for rapid detection of Strep ... Strep A test excels at detection of Strep ... colonization samples. This CLIA Waived test uses a ... Strep A leaves little chance for misdiagnosis, minimizing ...
    The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
    ...
    Medicine Products: